Browsing by Subject "Drug half life"

Article

About mentioning quality of preparation and quality control of radiopharmaceuticals used in nuclear medicine procedures [3]

Wozniak, Greta; Georgoulias, Panagiotis; Archimandritis, Spiros; Dimakopoulos, Nikolaos; Fezoulidis, Ioannis (2006)

Article

Antiretrovirals for HIV exposure prophylaxis

Nikolopoulos, Georgios K.; Tsiodras, Sotirios; Bonovas, Stefanos; Hatzakis, A. (2012)

Infection with Human Immunodeficiency Virus (HIV) remains a global public health problem. Although the epidemic has not been completely controlled, there was considerable progress in HIV prevention and treatment during the ...

Article

Antivirals used for influenza chemoprophylaxis

Tsiodras, Sotirios; Nikolopoulos, Georgios K.; Bonovas, Stefanos (2012)

Current data about the role of adamantanes and neuraminidase inhibitors (NIs) in the chemoprophylaxis against influenza viruses were reviewed. We found significant evidence favouring the role of NIs in the chemoprophylaxis ...

Article

Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction

Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)

The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...

Article

Management of leptomeningeal malignancy

Pentheroudakis, George; Pavlidis, Nicholas (2005)

Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane. Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with ...

Article

Multicentre phase II pharmacological evaluation of rhizoxin

McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

Article

Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study

Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, Nicholas (2002)

We characterized the toxicity and determined the maximum tolerated dose of non-break weekly paclitaxel (Taxol) in chemotherapy-naive cancer patients, and studied pharmacokinetics of the formulation vehicle Cremophor-EL ...

Article

Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study

Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)

Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...

Article

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group

Briassoulis, E. Ch; Judson, Ian Robert; Pavlidis, Nicholas; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K. C.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. R. (2000)

Purpose: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent ...

Article

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies

Schellens, J. H. M.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, Stanley B.; Dombernowsky, P.; Paridaens, R.; Oosterom, A. T. Van; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, Nicholas; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, Cristiana; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. (2002)

Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...

Article

Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy

Pentheroudakis, George; Pappas, P.; Golfinopoulos, Vassilis; Fountzilas, George; Nikolaidou, M.; Boumba, V. A.; Vougiouklakis, T.; Nikiforidis, L.; Tzamakou, E.; Siarabi, O.; Marselos, M.; Pavlidis, Nicholas (2007)

Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine ...

Article

Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors

Briassoulis, E. Ch; Pentheroudakis, George; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2004)

Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...